[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

ANI Pharma Inc (ANIP)

ANI Pharma Inc (ANIP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,672,904
  • Shares Outstanding, K 22,970
  • Annual Sales, $ 883,370 K
  • Annual Income, $ 78,340 K
  • EBIT $ 236 M
  • EBITDA $ 328 M
  • 60-Month Beta 0.44
  • Price/Sales 1.91
  • Price/Cash Flow 7.40
  • Price/Book 2.83

Options Overview Details

View History
  • Implied Volatility 34.72% (+0.10%)
  • Historical Volatility 31.10%
  • IV Percentile 9%
  • IV Rank 20.29%
  • IV High 58.60% on 02/23/26
  • IV Low 28.64% on 08/13/26
  • Expected Move (DTE 19) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 124
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 5,504
  • Open Int (30-Day) 4,968
  • Expected Range 72.83 to 72.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $1.77
  • Number of Estimates 3
  • High Estimate $1.83
  • Low Estimate $1.66
  • Prior Year $1.64
  • Growth Rate Est. (year over year) +7.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.61 +0.30%
on 08/28/26
83.21 -12.47%
on 08/06/26
-8.21 (-10.13%)
since 07/28/26
3-Month
72.61 +0.30%
on 08/28/26
87.19 -16.47%
on 07/07/26
-8.28 (-10.21%)
since 05/28/26
52-Week
70.15 +3.82%
on 03/13/26
99.50 -26.80%
on 09/10/25
-19.70 (-21.29%)
since 08/28/25

Most Recent Stories

More News
2 Reasons to Like ANIP (and 1 Not So Much)

2 Reasons to Like ANIP (and 1 Not So Much)

ANIP : 72.83 (-0.93%)
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company –

ANIP : 72.83 (-0.93%)
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors 

– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the...

ANIP : 72.83 (-0.93%)
1 Russell 2000 Stock to Target This Week and 2 We Brush Off

1 Russell 2000 Stock to Target This Week and 2 We Brush Off

RVLV : 22.91 (-0.30%)
ANIP : 72.83 (-0.93%)
PUMP : 10.98 (-1.79%)
The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call

The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call

ANIP : 72.83 (-0.93%)
Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks

ANIP : 72.83 (-0.93%)
ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration

ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration

ANIP : 72.83 (-0.93%)
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance

ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance

ANIP : 72.83 (-0.93%)
ANI: Q2 Earnings Snapshot

ANI: Q2 Earnings Snapshot

ANIP : 72.83 (-0.93%)
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-yearPurified Cortrophin® Gel net revenues of $117.1 million, an increase of 43.5%...

ANIP : 72.83 (-0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone...

See More

Key Turning Points

3rd Resistance Point 74.96
2nd Resistance Point 74.44
1st Resistance Point 73.64
Last Price 72.83
1st Support Level 72.32
2nd Support Level 71.80
3rd Support Level 71.00

See More

52-Week High 99.50
Fibonacci 61.8% 88.29
Fibonacci 50% 84.82
Fibonacci 38.2% 81.36
Last Price 72.83
52-Week Low 70.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.